Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MusclePlate

Financiado

Human skeletal muscle platform for disease modelling and high-throughput drug sc...

Human skeletal muscle platform for disease modelling and high-throughput drug screening Neuromuscular disorders (NMDs) are a collection of pathologies that affect the skeletal muscle (SkM) function and lead to reduced mobility, breathing issues and death. Most NMDs are incurable and existing therapies are generally i... ver más

31/10/2024

iMM

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-10-31

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

iMM

150.00K€ | Lider

INESC MN

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

GPSorganoids Generation of Position Specific organoids to study human neu... 3M€ Cerrado

MUSCLEGUY A novel muscle disorders 3D in vitro system for drug screeni... 150K€ Cerrado

EIN2020-112381 MODELIZACION DE ENFERMEDADES NEURODEGENERATIVAS 15K€ Cerrado

ORGESTRA Organoid technologies for disease modeling, drug discovery a... 3M€ Cerrado

ReprOids Reprogramming of somatic cells into organOids: patient-centr... 3M€ Cerrado

STEMBANCC Stem cells for Biological Assays of Novel drugs and prediCti... 55M€ Cerrado

Duración del proyecto: 20 meses Fecha Inicio: 2023-02-22
Fecha Fin: 2024-10-31

Líder del proyecto

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Neuromuscular disorders (NMDs) are a collection of pathologies that affect the skeletal muscle (SkM) function and lead to reduced mobility, breathing issues and death. Most NMDs are incurable and existing therapies are generally ineffective. The major contributor for the lack of NMD therapies is the absence of human NMD research models, applicable for the screening and validation of therapeutic candidates. Our goal for this project is to develop an in vitro platform containing highly biomimetic and functional SkM analogues, where NMDs can be modelled with the aim of testing drug candidates, in a reliable, high-throughput (HT), and quick manner. The platform will consist of 96 individual 3D tissue units, generated from the myogenic differentiation of human induced pluripotent stem cells (hiPSCs). To induce biomimetic and mature tissue formation, the platform will combine a unique topographical design with a light-stimulation system for optogenetic control of SkM contraction. Using image-based assays and computational algorithms, we will be able to automatically extract and quantify the SkM phenotypical (e.g. intracellular structure) and functional (e.g. contraction speed/force) parameters. To show NMD modelling ability within the platform, we will knockout BIN1, a gene whose mutated form is involved in the onset of centronuclear myopathy (CNM), a fatal and incurable NMD. The validity of the NMD model as a drug discovery platform will be demonstrated by testing compounds with known therapeutic activity. This proof of concept project will lay the ground work for a spin-off company devoted to HT drug screening for NMDs. The successful development of this platform will provide an invaluable tool for pharmaceutical research, allowing accurate, convenient and cost-effective identification of novel drugs and therapeutic targets for NMDs and, ultimately contributing to the acceleration of novel therapies for NMD patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores